Treatment of venous thromboembolism: guidelines translated for the clinician.
Venous thromboembolism is a major cause of morbidity and mortality affecting over 2 million people in the United States each year. The American College of Chest Physicians (ACCP) published their first consensus statement on antithrombotic therapy in 1986, and the most recent guidelines from the ACCP on this topic were released in 2008. We aim to summarize the most recent ACCP guidelines on therapy for venous thromboembolism with practical application and interpretation for the practicing physician. We will briefly review the rating system used in the guidelines for the level of evidence and the strength of the recommendation. We will then discuss the recommendations for initial anticoagulant therapies including low molecular weight heparin, unfractionated heparin, and fondaparinux for patients with both deep vein thrombosis (DVT) and pulmonary embolism (PE). A discussion of the guidelines on duration of anticoagulant therapy with a vitamin K antagonist is also included. In addition, we will address the use of thrombolytic therapy and inferior vena cava filter placement for DVT and PE. Prevention of postphlebitic syndrome is discussed as well. We will conclude with a brief discussion of future directions including several novel therapeutic anticoagulants.
Houman Fekrazad
M
M
Division of Hematology/Oncology, University of New Mexico, Albuquerque, NM, USA.
Lopes
Renato D
RD
Stashenko
Gregg J
GJ
Alexander
John H
JH
Garcia
David
D
D000925:Anticoagulants / Q000627:therapeutic use; D006801:Humans; D017410:Practice Guidelines as Topic; D015912:Thrombolytic Therapy; D016306:Vena Cava Filters; D054556:Venous Thromboembolism / Q000188:drug therapy / Q000628:therapy*
D000925:Anticoagulants